All Machine Learning (ML) articles
-
NewsLabGenius and LG Chem partner on AI-driven cancer antibodies
LabGenius Therapeutics has partnered with LG Chem to develop next-generation multispecific antibodies targeting solid tumours. The collaboration combines AI-driven drug discovery with oncology development expertise to identify therapeutics with improved selectivity and reduced toxicity.
-
NewsAI-powered $6M project targets new Alzheimer’s treatments
A $6 million NIH-funded collaboration between Indiana University School of Medicine and Luddy School of Informatics aims to deploy AI and machine learning to identify promising Alzheimer’s drug candidates, screening billions of compounds to overcome traditional discovery bottlenecks.
-
ReportAI in Drug Discovery: Progress, Limits and What Comes Next
AI has attracted enormous investment across drug discovery, but major questions still remain around validation, reproducibility and real-world application. In our latest Beyond the Lab report, experts discuss where the technology is starting to influence discovery workflows – and where limitations continue to slow adoption.
-
ArticleFrom chemist to AI agent builder: inside the rise of agentic AI in drug discovery
Dr Raminderpal Singh speaks with Dr Srijit Seal about why specialised AI agents are outperforming general-purpose models in drug discovery and what a new consortium paper shows about their use in practice.
-
ArticleMachine learning identifies biological signals linked to emotional hunger
Researchers at Phenomix Sciences are using machine learning and genetic risk scoring to investigate emotional hunger, an obesity phenotype linked to emotional and reward-driven eating behaviours. Dr Timothy O’Connor discusses how the approach could improve patient stratification, obesity research and treatment selection.
-
NewsAI platform identifies novel gp130 inhibitor for colorectal cancer
An AI-assisted drug discovery platform using transfer learning has identified a promising gp130 inhibitor for colorectal cancer.
-
NewsAI identifies 23 antiviral candidates for Bundibugyo Ebola strain
US researchers have deployed artificial intelligence and molecular docking software to identify 23 antiviral compounds with potential activity against Bundibugyo Ebolavirus, as the rare strain continues to spread in the Democratic Republic of Congo with a fatality rate approaching 40 percent.
-
NewsOutSee wins Longitude Prize award for ALS target discovery
OutSee has secured a Discovery Award from the Longitude Prize on ALS, providing £100,000 in funding and access to genomic data from 9,000 patients. The company will deploy its AI-driven Nomaly platform to identify novel therapeutic targets for amyotrophic lateral sclerosis over a nine-month research programme.
-
NewsAI-designed viral vectors achieve 50-fold brain enrichment over AAV9
WhiteLab Genomics has presented preclinical data showing that viral vectors designed using artificial intelligence achieved approximately 50-fold higher DNA enrichment in the brain compared to AAV9, with no detectable liver signal following intravenous administration in mice.
-
NewsAI system transforms weak antibiotics into powerful treatments
University of Pennsylvania researchers have developed ApexGO, an AI system that refines imperfect antibiotic candidates through calculated modifications rather than database screening.
-
NewsAI system reduces animal testing in drug discovery by 50 percent
German researchers have developed genESOM, a generative AI system that could reduce animal numbers in preclinical drug testing by 30 to 50 percent.
-
NewsNew framework evaluates AI reliability in immune system prediction
Researchers at the University of South Florida have developed a comprehensive framework to test how accurately AI systems can predict immune responses, addressing critical questions about the reliability of computational tools in drug discovery.
-
NewsMachine learning identifies five distinct Parkinson’s disease subtypes
A new study from VIB and KU Leuven has revealed that Parkinson’s disease comprises five distinct molecular subtypes, each requiring tailored therapeutic approaches.
-
ArticleThe scale divide: competing strategies in AI drug discovery
Two approaches to AI in preclinical drug discovery are diverging, from multi-thousand GPU systems to models with only a handful of parameters, with early results raising questions about which will deliver.
-
ArticleFrom leaderboards to lab notebooks: AI designs reach preclinical testing
For years, AI drug discovery has been judged on benchmark performance. Now, a set of studies shows what happens when those designs are made and tested in preclinical settings.
-
ArticleThe future of academic core labs: scaling operational excellence without increasing staff
The grounds have shifted the foundations of academic core facilities and the current climate demands their strategic agility in order to thrive. Boyd Butler at Molecular Devices reveals how these labs can capitalise on this opportunity to increase value and efficiency.
-
ArticleBeyond serendipity: rational design and AI’s expansion of the undruggable target landscape
For decades, drugging the ‘undruggable’ was thought to require luck rather than logic. Today, AI is transforming serendipity into strategy by enabling rational, data-driven approaches to previously inaccessible targets.
-
ArticleOperational data: the hidden driver of faster drug discovery
The key to faster, smarter drug discovery lies in data that’s often overlooked. By exposing hidden delays and inefficiencies, this data enables teams to shorten discovery cycles and progress promising candidates faster.
-
InterviewFrom scientist to bioinformatician: how AI coding tools dissolved the activation energy barrier
A biotech CEO with decades of scientific experience but sporadic coding practice gained practical bioinformatics capabilities in six weeks using AI coding assistants.
-
NewsNew AI-designed T-cell engager LGTX-101 to be presented at AACR in San Diego
LabGenius Therapeutics will present preclinical data for LGTX-101, its AI-designed Nectin-4 x CD3 T-cell engager, at AACR 2026 in San Diego.